6 research outputs found

    Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy

    Get PDF
    Background Direct-acting antivirals (DAAa) cure hepatitis C virus (HCV) infections in 95% of infected patients. Modeling studies predict that universal HCV treatment will lead to a decrease in the incidence of new infections but real-life data are lacking. The incidence of HCV among Dutch human immunodeficiency virus (HIV)–positive men who have sex with men (MSM) has been high for >10 years. In 2015 DAAs became available to all Dutch HCV patients and resulted in a rapid treatment uptake in HIV-positive MSM. We assessed whether this uptake was followed by a decrease in the incidence of HCV infections. Methods Two prospective studies of treatment for acute HCV infection enrolled patients in 17 Dutch HIV centers, having 76% of the total HIV-positive MSM population in care in the Netherlands. Patients were recru

    A novel haemocytometric covid-19 prognostic score developed and validated in an observational multicentre european hospital-based study

    Get PDF
    COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients

    L'ordinamento giuridico italiano nello "spazio di libertĂ . sicurezza e giustizia"

    Get PDF
    Una delle più significative novità introdotte con il Trattato di Lisbona è stata quella di aver mutato profondamente l’assetto precedente dello spazio di libertà sicurezza e giustizia. Ciò ha determinato un sostanziale cambiamento della tipologia di atti normativi che dal 2009 in poi sono emanati in questa materia ed anche gli atti precedenti hanno acquistato dal 1° dicembre 2014 piena efficacia, con tutela giurisdizionale della Corte di giustizia e la possibilità di procedimento d’infrazione da parte della Commissione. La chiave di lettura della ricerca è stata quella di verificare l’evoluzione che hanno avuto le fonti europee e quelle interne in tema di cooperazione giudiziaria e di polizia, analizzando quelle sfere di criminalità particolarmente gravi con dimensione transnazionale che richiedono non solo una maggiore collaborazione fra gli Stati, ma l’introduzione di norme minime unitarie. I settori in cui è maggiore l’interesse europeo ad una cooperazione ed armonizzazione delle norme penali e che il Trattato di Lisbona conferisce alla competenza del Parlamento e del Consiglio dell’Unione sono la lotta al terrorismo, la tratta degli esseri umani, il traffico illecito degli stupefacenti, il riciclaggio di denaro, la criminalità informatica ed organizzata. Tutti questi temi sono stati analiticamente studiati in questa ricerca

    High treatment uptake in human immunodeficiency virus/ hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands

    No full text
    Background The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV. Methods Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response. Results Of 23574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14, and a pegylated interferon-alfa–based regimen had failed in 54. Conclusions Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients
    corecore